Guardant Health announces collaboration with Boehringer Ingelheim

Guardant Health (GH) announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360 CDx liquid biopsy as a companion diagnostic for zongertinib, an investigational covalent tyrosine kinase inhibitor that selectively inhibits HER2 while sparing epidermal growth factor receptor in non-small cell lung cancer. As part of the collaboration, the Guardant360 CDx blood test will provide genomic profiling of tumors to identify actionable biomarkers that allow targeted therapy selection and help identify NSCLC patients with HER2 mutations who may be eligible for treatment with Boehringer’s investigational zongertinib after it is approved by health authorities.